针对淀粉样蛋白不同靶点的抗体研究进展

Research progress on antibodies against different targets of amyloid

阿尔茨海默病(Alzheimer's disease,AD)是一种起病隐匿的进行性发展的神经系统变性疾病。AD发病机理十分复杂,可能是多因素相互作用的结果。β-淀粉样蛋白(Aβ)级联假说是既往针对其发病机制中的经典学说,在此学说的指导下投入了大量的药物研发,大多研发将Aβ作为研究靶点试图预防或延缓AD的发生发展。该文就目前国外针对淀粉样蛋白不同形式的抗体研究进行阐述,希望可以帮助研究人员了解淀粉样蛋白相关抗体药物的研发现状,为以后研制AD新药提供思路。

Alzheimer's disease(AD)is a progressive neurodegenerative disease with insidious onset.The pathogenesis of AD is very complex and may be the result of multifactorial interaction.Theβ-amyloid(Aβ)cascade hypothesis is currently the classic theory of its pathogenesis.The abnormal accumulation of Aβis closely related to the occurrence and development of the disease.Under the guidance of this theory,a large number of drug research has been invested,and most of the research takes Aβas a target to try to prevent or delay the occurrence and development of AD.This article elaborates on the research on different forms of amyloid antibodies in abroad,hoping to help researchers understand the current status of amyloid-related antibody drug research and provide ideas for the future development of new AD drugs.